Related Experiment Video
Updated: Dec 10, 2025
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer
Hironobu Minami1, Yuichi Ando2, Kenji Tamura3
1Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan hminami@med.kobe-u.ac.jp.
Background/Aim:
The prolactin receptor (PRLR) is implicated in the tumorigenesis of breast and prostate cancers where it drives cell proliferation, survival, and migration. LFA102 is a humanized monoclonal antibody against PRLR with promising preclinical antitumor activity. To determine the maximum tolerated dose or a recommended dose, and to delineate the pharmacokinetic profile of LFA102 in Japanese patients, we conducted a phase I study.
Patients And Methods:
LFA102 was intravenously infused every 4 weeks to patients with advanced breast or castration-resistant prostate cancer, and the dose increased from 3 to 40 mg/kg.
Results:
Fourteen patients were treated, and toxicities were reported in 9 (64%) patients. They were all grade 1 or 2, and the most frequently observed toxicity was nausea (3 patients, 21%). No dose-limiting toxicities were observed. LFA102 did not show antitumor activity as a single agent.
Conclusion:
Treatment with LFA102 was well tolerated.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019